Abandoning clinical trial safeguards won’t boost local industry

摘要

Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the udmoney coming from international pharmaceutical companies. But as investment grows in udIndia, China, and other emerging competitors, some people argue we need to make Australia udmore attractive to such investment. One of their solutions is to water down the ethics udapproval process.